Luye Pharma logo

2186 - Luye Pharma Share Price

HK$5.64 0.0  0.7%

Last Trade - 8:08am

Sector
Healthcare
Size
Mid Cap
Market Cap £1.80bn
Enterprise Value £1.94bn
Revenue £665.0m
Position in Universe 492nd / 5945
Bullish
Bearish
Unlock 2186 Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

2186 Revenue Unlock 2186 Revenue

Net Income

2186 Net Income Unlock 2186 Revenue

Normalised EPS

2186 Normalised EPS Unlock 2186 Revenue

PE Ratio Range

2186 PE Ratio Range Unlock 2186 Revenue

Dividend Yield Range

2186 Dividend Yield Range Unlock 2186 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
2186 EPS Forecasts Unlock 2186 Revenue
Profile Summary

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated July 2, 2003
Public Since July 9, 2014
No. of Shareholders: n/a
No. of Employees: 4,240
Sector Healthcare
Industry Pharmaceuticals
Index Hang Seng Composite , Hang Seng Composite LargeCap & MidCap , Hang Seng Mainland 100 , Hang Seng Composite MidCap , Hang Seng Composite Mid & SmallCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 3,268,965,343
Free Float (0.0%)
Eligible for
ISAs
SIPPs
2186 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 2186
Upcoming Events for 2186
Similar to 2186
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.